Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy

Publish Year: 1404
نوع سند: مقاله ژورنالی
زبان: English
View: 137

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_ARCHRAZI-80-4_003

تاریخ نمایه سازی: 3 شهریور 1404

Abstract:

VLPs are spontaneously generated from viral capsid proteins. VLPs imitate genuine viruses visually and physiologicallybut lack viral DNA. Various VLP designs provide structural and functional appeal. Spontaneous polymerization of viral capsid proteins may result in VLPs with geometrical symmetry, which are often icosahedral, spherical, or rod-like.Moreover, functionalized VLPs may precisely target cancer cells and recruit macrophages to destroy them. The ability to target tumors for therapeutic drug delivery through using VLP-based delivery platforms in novel and intriguing aspects related to cancer treatment is the primary goal of VLP design. Cancer therapies require precise targeting of diagnostic or therapeutic elements to tumor cells while avoiding healthy cells and tissues. VLPs offer an innovative approachas site-specific drug delivery systems reducing systemic toxicity and injury to healthy cells. Immunotherapy, which boosts the host's immune system, has fewer side effects. Cancer vaccines aim to induce an immune response that provides protection against tumor cells. Due to their naturally fitted particle size and repetitive structural order, VLPs may be employed as a vaccine without any adjuvant. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy.

Keywords:

drug delivery , Gene therapy , Multi-capsid VLPs , Virus-like particles (VLPs )

Authors

Hadi Esmaeili Gouvarchin Ghaleh

Applied Virology Research Center, Biomedicine Technologeis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Mostafa Mahabadi

Applied Virology Research Center, Biomedicine Technologeis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Mahdieh Farzanehpour

Applied Virology Research Center, Biomedicine Technologeis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Ali Zahiri

Students Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Majid Mirzaei Nodoushan

Applied Virology Research Center, Biomedicine Technologeis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, ...
  • Taghizadeh MS, Niazi A, Afsharifar A. Virus-like particles (VLPs): A ...
  • Tariq H, Batool S, Asif S, Ali M, Abbasi BH. ...
  • Martins SA, Santos J, Silva RD, Rosa C, Cabo Verde ...
  • Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to ...
  • Travassos R, Martins SA, Fernandes A, Correia JD, Melo R. ...
  • Mohsen MO, Gomes AC, Vogel M, Bachmann MF. Interaction of ...
  • Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, ...
  • Yan D, Wei Y-Q, Guo H-C, Sun S-Q. The application ...
  • Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles ...
  • Roldão A, Silva A, Mellado M, Alves P, Carrondo M. ...
  • Brémaud E, Favard C, Muriaux D. Deciphering the assembly of ...
  • Rohovie MJ, Nagasawa M, Swartz JR. Virus‐like particles: Next‐generation nanoparticles ...
  • Wang Y, Douglas T. Protein nanocage architectures for the delivery ...
  • Fu Y, Li J. A novel delivery platform based on ...
  • He J, Yu L, Lin X, Liu X, Zhang Y, ...
  • Naskalska A, Heddle JG. Virus-like particles derived from bacteriophage MS۲ ...
  • Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in ...
  • Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, ...
  • Lino CA, Caldeira JC, Peabody DS. Display of single-chain variable ...
  • Kolesanova E, Melnikova M, Bolshakova T, Rybalkina EY, Sivov I. ...
  • Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug ...
  • Hajeri PB, Sharma NS, Yamamoto M. Oncolytic adenoviruses: strategies for ...
  • SM Wold W, Toth K. Adenovirus vectors for gene therapy, ...
  • Wang M, Bergès R, Malfanti A, Préat V, Bastiancich C. ...
  • Zeng Q, Wen H, Wen Q, Chen X, Wang Y, ...
  • Chou M-I, Hsieh Y-F, Wang M, Chang JT, Chang D, ...
  • Galaway FA, Stockley PG. MS۲ viruslike particles: a robust, semisynthetic ...
  • Facciolà A, Visalli G, Laganà P, La Fauci V, Squeri ...
  • Hadj Hassine I, Ben M'hadheb M, Almalki MA, Gharbi J. ...
  • Parkin DM. The global health burden of infection‐associated cancers in ...
  • Vahdat MM, Hemmati F, Ghorbani A, Rutkowska D, Afsharifar A, ...
  • Wang JW, Roden RB. Virus-like particles for the prevention of ...
  • Zhao H, Zhou X, Zhou Y-H. Hepatitis B vaccine development ...
  • Shouval D, Ilan Y, Adler R, Deepen R, Panet A, ...
  • Fleites YA, Aguiar J, Cinza Z, Bequet M, Marrero E, ...
  • Braun M, Jandus C, Maurer P, Hammann‐Haenni A, Schwarz K, ...
  • Deo VK, Kato T, Park EY. Chimeric virus-like particles made ...
  • Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery ...
  • Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, ...
  • Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing ...
  • Torres-Vanegas JD, Cruz JC, Reyes LH. Delivery systems for nucleic ...
  • Puhl DL, D’Amato AR, Gilbert RJ. Challenges of gene delivery ...
  • Agranovsky A. Enhancing capsid proteins Capacity in plant virus-vector interactions ...
  • Peyret H, Steele JF, Jung J-W, Thuenemann EC, Meshcheriakova Y, ...
  • Naso MF, Tomkowicz B, Perry III WL, Strohl WR. Adeno-associated ...
  • Czapar AE, Steinmetz NF. Plant viruses and bacteriophages for drug ...
  • Malanchere-Bres E, Payette P, Mancini M, Tiollais P, Davis H, ...
  • Hoffmann DB, Gruber J, Böker KO, Deppe D, Sehmisch S, ...
  • An M, Raguram A, Du SW, Banskota S, Davis JR, ...
  • Liu S, Hu M, Liu X, Liu X, Chen T, ...
  • Dai S, Wang H, Deng F. Advances and challenges in ...
  • Hsieh S-C, Liu I-J, King C-C, Chang G-J, Wang W-K. ...
  • Ponndorf D, Meshcheriakova Y, Thuenemann EC, Dobon Alonso A, Overman ...
  • Joung JK, Cabeceiras P. Enhanced virus-like particles and methods of ...
  • نمایش کامل مراجع